In ReCell, AVMXY has one of the very few regenerative medicine...

In ReCell, AVMXY has one of the very few regenerative medicine products currently on the market. We
believe it has the potential to change the standard of care for chronic wounds and burned or damaged skin.
Highly lucrative aesthetic applications add to the to the long term appeal.


? ReCell is gaining traction in its core European and Australian markets after early commercialization
missteps by previous management proved an impediment to mass adoption in those geographies.
Additionally, AVMXY is proactively expanding into new geographies. In the last nine months, it signed
new distribution agreements in China, the Middle East and Italy.

? Even with relatively modest mid-single digit penetration rates in major addressable markets across key
indications in the next five years, ReCell would be used in nearly 200k procedures and generate nearly
$140MM in revenue.

"http://www.avitamedical.com/?ob=3&id=340"

$140 million with p/v ratio of 10 is a $1.4 billion market cap in 5 years.

this is not from hot copper spruker but a creditable USA invest company. B. Riley. http://brileyco.com/